Mucosal chemokine adjuvant enhances synDNA vaccine-mediated responses to SARS-CoV-2 and provides heterologous protection in vivo점막 케모카인 보조제는 SARS-CoV-2에 대한 synDNA 백신 매개 반응을 향상시키고 생체 내 이종 보호를 제공합니다Article Published on 2022-07-192022-09-11 Journal: Cell Reports Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant approach CCL27 CD8 cell-mediated response Cell-mediated responses chemokine claimed coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Delta VOC DNA DNA plasmid DNA vaccine Efficacy ENhance Frequency Heterologous heterologous challenge humoral IFNγ immunogenicity immunological in vivo interferon gamma mucosa mucosal mucosal surface mucosal surfaces mucosal. pandemic Plasmid Protective provide respiratory respiratory mucosa response SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines significant effect Spike protein Spike-specific antibody T cell T cells unique Vaccine vaccine efficacy variants of concern Viral viral control VOCs wild-type [DOI] 10.1016/j.xcrm.2022.100693 PMC 바로가기 [Article Type] Article
Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants조상 균주 백신 접종 마우스의 오미크론 부스터는 델타 및 오미크론 변이체 모두에 대한 보호 면역 강화Article Published on 2022-07-062022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, [키워드] Against antibody Antibody Response Antibody responses boost booster booster vaccination CD8 COVID-19 vaccine cross-protective cross-reactive cross-reactivity cross-reactivity. Delta DNA vaccine DNA vaccines elicited Epidemic immunized mice mice Neutralizing antibody response neutralizing antibody responses no significant difference omicron Omicron variant Omicron variants Omicron-matched vaccine RBD binding SARS-CoV-2 significant difference Specific Spike protein Spike proteins strain T cell T cell response T cell responses the spike protein Vaccine variant variants were measured Wuhan strain [DOI] 10.3389/fimmu.2022.897879 PMC 바로가기 [Article Type] Article
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label TrialSARS-CoV-2 DNA 백신 INO-4800, 1상 공개 라벨 시험에서 강화될 수 있는 내구성 면역 반응 유도Clinical Trial Published on 2022-06-012022-09-12 Journal: The Journal of Infectious Diseases [Category] Coronavirus, COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] activated acute respiratory syndrome Adults adverse event age Antibody Response Antigen being booster booster dose CD8+ T cell clinical clinical trial coronavirus coronavirus disease COVID-19 DNA DNA vaccine dosage dose effective Electroporation evaluated Frequency full-length healthy homologous immune response immune responses immunogenicity increase in INO-4800 intradermal injection Mild MOST pandemic Participants Phase 1 primary dose response Safe Safety. SARS-CoV-2 second dose Serious Adverse Events significantly increased subsequent Support T cell Trial Vaccine [DOI] 10.1093/infdis/jiac016 PMC 바로가기 [Article Type] Clinical Trial
Development of DNA Vaccine Candidate against SARS-CoV-2Article Published on 2022-05-152023-07-09 Journal: Viruses [Category] COVID19(2023년), [키워드] COVID-19 DNA vaccine SARS-CoV-2. [DOI] 10.3390/v14051049 PMC 바로가기
Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primatesINO-4800 및 INO-4802를 사용한 프라임-부스트 백신 요법은 비인간 영장류에서 SARS-CoV-2에 대한 면역 반응을 증대 및 확대합니다.Article Published on 2022-05-092022-09-11 Journal: Vaccine [Category] Coronavirus, COVID19(2023년), SARS, 변종, 비임상, [키워드] ACE2 Antibody Response Antibody responses blocking activity Booster vaccine booster vaccines characterized clinical evaluation COVID-19 DNA DNA vaccine Electroporation evaluated expansion homologous or heterologous immune evasion immune response Immunity immunogenicity INO-4800 Intradermal macaque natural infection Neutralizing pandemic portion question regimen regimens rhesus macaque rhesus macaques SARS-CoV-2 SARS-CoV-2 sequence SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2. shifting Strains Support T cell T cells These data Transmissibility vaccination Vaccine variant variants of concern wild-type SARS-CoV-2 Wuhan-Hu-1 [DOI] 10.1016/j.vaccine.2022.03.060 PMC 바로가기 [Article Type] Article
Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences인도-아프리카 서열을 기반으로 하는 EDIII-NS1 컨센서스 디자인을 암호화하는 새로운 뎅기열 DNA 백신의 면역 프로필 및 반응Article Published on 2022-05-042022-09-11 Journal: Molecular therapy : the journal of the American So [Category] MERS, 변종, 진단, [키워드] antibody Antibody-dependent enhancement Antigen antigens clinical isolates coding sequence Consensus consensus sequence conserved COVID-19 pandemic Dengue dengue surveillance. dengue virus DENV-2 DNA DNA vaccine domain domain III EDIII domain emerging viruses envelope protein epitope Epitopes expand Genotype highlight IgG1 immune immune response immunogenic Immunoglobulin India Indo-African interferon isolate mice neutralizing antibody non-structural protein NS1 protein passive transfer protein expression response sequence Sequencing sera serotype serotype-specific staining Stand Structural analysis Surveillance T cell T cell responses transfer translation vaccination Vaccine vaccine candidate Vaccine design Viral Viral variants virulent viruses whole genome Whole genome sequencing [DOI] 10.1016/j.ymthe.2022.01.013 PMC 바로가기 [Article Type] Article
Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters Research Published on 2022-04-262022-10-05 Journal: NPJ Vaccines [Category] 유전자 메커니즘, [키워드] BALB/c C57BL/6 demonstrated DNA plasmid DNA vaccine effective evaluated expressing hamster hamsters Health immunized immunogenic peptide Infection Infectious virus lung mice morbidity and mortality neutralizing antibody pathology PROTECT reduce reducing robust SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 variant severe disease spike gene the SARS-CoV-2 vaccination Vaccine Vaccines viral burden was reduced weight loss [DOI] 10.1038/s41541-022-00461-5 [Article Type] Research
Successive Site Translocating Inoculation Improved T Cell Responses Elicited by a DNA Vaccine Encoding SARS-CoV-2 S ProteinArticle Published on 2022-04-192023-07-09 Journal: Frontiers in Immunology [Category] COVID19(2023년), [키워드] Antibody Response DNA vaccine protein vaccine successive site translocating inoculation. T cell response [DOI] 10.3389/fimmu.2022.875236 PMC 바로가기
In silico design of influenza a virus artificial epitope-based T-cell antigens and the evaluation of their immunogenicity in miceArticle Published on 2022-04-012023-06-24 Journal: Journal of biomolecular structure & dynamics [Category] 신종인플루엔자, [키워드] DNA vaccine immunogenicity in silico design influenza virus. T-cell epitope-based antigens [DOI] 10.1080/07391102.2020.1845978 PMC 바로가기
Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults스파이크 또는 스파이크 및 뉴클레오캡시드 단백질의 코딩 영역을 포함하는 2개의 재조합 DNA COVID-19 백신의 안전성 및 면역원성: 건강한 성인을 대상으로 한 2개의 공개 라벨, 비무작위, 1상 시험에 대한 중간 분석Clinical Trial Published on 2022-03-012022-09-11 Journal: The Lancet. Microbe [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료법, [키워드] adverse event adverse events analysed Antibody Response blood sample Blood samples coding region collected COVID-19 vaccine development DNA DNA vaccine domain dose of vaccination doses drug energy ENhance enrolled fatigue first vaccination group healthy hospital humoral immunogenicity individuals induce intention-to-treat population interim analysis intervals intramuscularly Mild Ministry of Health moderate neutralising antibody response nucleocapsid nucleocapsid protein Open-label participant Participants Phase 1 phase 1 trial Plasmid plasmid DNA positive Primary outcome RBD recombinant DNA Registered reported Safe Safety SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2-specific T-cell responses Science screened second dose secondary outcome Serological testing South Korea Spike protein T-cell responses tested the RBD the SARS-CoV-2 the spike protein the vaccines Trade treatment-emergent adverse event Trial trial participant trials vaccination Vaccine vaccine dose vaccine immunogenicity Welfare were excluded [DOI] 10.1016/S2666-5247(21)00358-X PMC 바로가기 [Article Type] Clinical Trial